Jefferies Financial Group Inc. Invests $10.24 Million in Stryker Corporation $SYK

Jefferies Financial Group Inc. purchased a new position in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 32,511 shares of the medical technology company’s stock, valued at approximately $10,236,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new position in shares of Stryker in the second quarter worth $205,000. Marshall Wace LLP increased its stake in shares of Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after acquiring an additional 77,831 shares during the last quarter. Nebula Research & Development LLC purchased a new stake in shares of Stryker during the second quarter worth $219,000. Finally, HUB Investment Partners LLC acquired a new stake in Stryker during the second quarter valued at $253,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on SYK shares. Citigroup restated a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Leerink Partners reduced their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Piper Sandler lowered their price target on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, Canaccord Genuity Group dropped their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Trading Down 2.3%

Stryker stock opened at $322.20 on Friday. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The company’s fifty day moving average price is $328.64 and its two-hundred day moving average price is $331.47. The company has a market capitalization of $123.58 billion, a price-to-earnings ratio of 33.39, a PEG ratio of 2.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insider Buying and Selling at Stryker

In related news, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the transaction, the director owned 2,301,375 shares in the company, valued at $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 over the last 90 days. Insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.